Imunon chair receives stock grant as salary

Tardugno Michael H reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Tardugno Michael H reported acquisition or exercise transactions in this Form 4 filing.

Imunon, Inc. Executive Chairman Michael H. Tardugno reported a compensation-related stock grant. He received 3,484 shares of Common Stock as a grant or award at $2.20 per share, described as stock granted in lieu of cash for base salary.

After this grant, he holds 8,749 shares of Imunon Common Stock directly. Separately, an indirect entry shows 4,622 shares held through a 401(k) Plan, reflecting retirement-plan ownership rather than an open-market transaction.

Insider Trade Summary

Grant/Award: 3,484 shares

Grant/Award 2 txns

Insider Tardugno Michael H

Role Executive Chairman of Board

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	3,484	$2.20	$8K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 8,749 shares (Direct); Common Stock — 4,622 shares (Indirect, By 401(k) Plan)

Footnotes (1)

1. F1. Stock granted in lieu of cash for base salary

Key Figures

Stock grant shares: 3,484 shares Grant reference price: $2.20 per share Direct holdings after grant: 8,749 shares +1 more

4 metrics

Stock grant shares 3,484 shares Grant, award, or other acquisition of Common Stock

Grant reference price $2.20 per share Value used for compensation stock grant

Direct holdings after grant 8,749 shares Common Stock directly owned after transaction

Indirect 401(k) holdings 4,622 shares Common Stock held indirectly by 401(k) Plan

Key Terms

Grant, award, or other acquisition, 401(k) Plan, Common Stock, Executive Chairman of Board

4 terms

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

401(k) Plan financial

"nature_of_ownership: By 401(k) Plan"

A 401(k) plan is a workplace retirement account that lets employees set aside part of their pay into a tax-advantaged savings pot, often with employers adding matching contributions — like a workplace piggy bank for future income. It matters to investors because the amount people save and how employers fund these plans influence consumer spending, corporate payroll costs and the flow of money into financial markets, which can affect stock prices and company valuations.

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Executive Chairman of Board financial

"officer_title: Executive Chairman of Board"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Imunon (IMNN) report for Michael H. Tardugno?

Imunon reported that Executive Chairman Michael H. Tardugno received a grant of 3,484 shares of Common Stock. The shares were issued as compensation, specifically stock granted in lieu of cash for base salary, rather than an open-market purchase.

At what price was the Imunon (IMNN) stock grant to Michael H. Tardugno valued?

The 3,484-share grant to Michael H. Tardugno was valued at $2.20 per share. This reflects the reference price used for the compensation award, not a disclosed open-market trading price during the period.

How many Imunon (IMNN) shares does Michael H. Tardugno hold directly after the grant?

Following the reported grant, Michael H. Tardugno directly holds 8,749 shares of Imunon Common Stock. This figure represents his direct ownership position after receiving the 3,484-share compensation award on the reported transaction date.

What Imunon (IMNN) shares does Michael H. Tardugno hold indirectly through a 401(k) Plan?

The filing shows an indirect holding of 4,622 shares of Imunon Common Stock in a 401(k) Plan. This entry is categorized as a holding, reflecting retirement-plan ownership rather than a new market transaction in the company’s stock.

Was the Imunon (IMNN) stock grant to Michael H. Tardugno an open-market purchase or compensation?

The 3,484-share transaction was compensation, not an open-market purchase. It is coded as a grant or award, with a footnote stating the stock was granted in lieu of cash for base salary, indicating a non-cash salary component.

Does the Imunon (IMNN) Form 4 show any insider sales by Michael H. Tardugno?

The Form 4 does not report any insider sales by Michael H. Tardugno. It shows a stock grant of 3,484 shares as compensation and a separate 401(k) Plan holding entry, without any sale or disposition transactions indicated in the data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/27/2026 - 04:22 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tardugno Michael H

(Last) (First) (Middle)

C/O IMUNON, INC.

997 LENOX DRIVE, SUITE 100

(Street)

LAWRENCEVILLE NEW JERSEY 08648

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Imunon, Inc. [ IMNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Chairman of Board

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/22/2026		A		3,484(1)	A	$2.2	8,749	D
Common Stock								4,622	I	By 401(k) Plan

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Stock granted in lieu of cash for base salary

Remarks:

On August 21, 2025, the Issuer paid a 15% stock dividend, 0.15 shares of common stock per share of the Issuer's issued and outstanding shares of common stock, to stockholders of record as of August 7, 2025. As a result of the stock dividend, the shares of Issuer Common Stock have been adjusted accordingly versus any amounts previously reported by the Reporting Person.

	/s/ Susan Eylward, Attorney-in-Fact for Michael Tardugno	05/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)